Loading...
•
Dec 31, 2021
Ultragenyx Q4 2021 Earnings Report
Ultragenyx reported Q4 2021 financial results and provided a corporate update.
Key Takeaways
Ultragenyx reported a total revenue of $83.4 million for Q4 2021. The company made significant progress across its early and late-stage clinical pipeline and is preparing for the launch of Evkeeza in Europe.
Total revenue for Q4 2021 was $83.4 million.
Crysvita revenue in Ultragenyx territories was $55.5 million, including $50.2 million in collaboration revenue in the North American profit share territory.
Dojolvi product sales were $11.8 million.
The company had a cash balance of approximately $1.0 billion at the end of 2021.
Ultragenyx
Ultragenyx
Ultragenyx Revenue by Segment
Ultragenyx Revenue by Geographic Location
Revenue by Segment
Crysvita Revenue
CapyFin.comDojolvi Revenue
CapyFin.comMepsevii Revenue
CapyFin.comRevenue by Geographic Location
Europe Revenue
CapyFin.com Forward Guidance
Ultragenyx expects 2022 revenue for Crysvita in Ultragenyx territories to be between $250 million and $260 million and Dojolvi revenue to be between $55 million and $65 million.
Positive Outlook
- 2022 revenue for Crysvita in Ultragenyx territories to be between $250 million and $260 million.
- Dojolvi revenue to be between $55 million and $65 million.
- Submission of reimbursement dossiers expected in European countries in 2022 for Evkeeza.
- Dosing in the Pivotal Phase 2/3 Orbit study for UX143 is expected to begin in the first half of 2022.
- Phase 3 eNH3ance study of DTX301 expected to initiate in first half of 2022.
Revenue & Expenses
Visualization of income flow from segment revenue to net income